GRAL
Grail, Inc. Health Care Services-Medical Laboratories Russell 3000
$143.43Close
$5.8BMarket cap
$43.03 – $158.9252-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 98 · stronger than 98% of stocks over 12 months
- Accumulation up-day volume 2.1× down-day volume over 50 sessions
Cautions
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
10%
1wk
up 8.2%
price change
1mo
up 2.4%
price change
12-month return
up 57%
market up 11% ·
its own up 57%
F-score
—
— Not assessed
Altman Z″
-2.86
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.2×
price / book
Earnings yield
down 10.2%
EBIT / enterprise value
Cheaper than
29%
of the market · expensive
Revenue growth
up 17%
year on year
EPS growth
—
latest quarter
Sales growth
up 26%
latest quarter · -2 pts
ROE
down 16%
return on equity
Free cash margin
down 204%
-$299.9M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
7.4%
$10.62 a day · 2×ATR $122.18
RS
98 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
2.10
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 19.0% over the year, from 34m to 40m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 5, 2026
Last shock
Aug 6, 2026-15% in one session3.1× volumeon results+126% since
Financials
- Net -277%
- Free cash -204%
- Cash
- Long-term debt
| FY2022Jan 1, 2023 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $55.5M | $93.1M | $125.6M | $147.2M |
| Operating income | -$5.4B | -$1.5B | -$2.2B | -$562.2M |
| Net income | -$5.4B | -$1.5B | -$2.0B | -$408.4M |
| Net margin | -9719% | -1574% | -1614% | -277% |
| Earnings per share | -$173.89 | -$47.21 | -$63.54 | -$11.11 |
| Free cash flow | -$584.2M | -$608.7M | -$582.4M | -$299.9M |
| Free cash margin | -1052% | -654% | -464% | -204% |
| Cash | $241.6M | $97.3M | $214.2M | $249.7M |
| Shareholders' equity | — | — | $2.5B | $2.6B |
| Shares outstanding | — | 0 | 33.89m | 40.33m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 12, 2026 | Annual ↗ | Dec 31, 2025 | 71d |
| Nov 13, 2025 | Quarterly ↗ | Sep 30, 2025 | 44d |
| Aug 13, 2025 | Quarterly ↗ | Jun 30, 2025 | 44d |
| May 14, 2025 | Quarterly ↗ | Mar 31, 2025 | 44d |
| Mar 5, 2025 | Annual ↗ | Dec 31, 2024 | 64d |
| Nov 13, 2024 | Quarterly ↗ | Sep 30, 2024 | 44d |
| Aug 13, 2024 | Quarterly ↗ | Jun 30, 2024 | 44d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 5, 2026 | Results ↗ |
| Jun 22, 2026 | Shareholder vote ↗ |
| Jun 1, 2026 | Director or officer change · Other events ↗ |
| May 5, 2026 | Results ↗ |
| Feb 19, 2026 | Results · Other events ↗ |
| Jan 12, 2026 | Results ↗ |
| Nov 14, 2025 | Other events ↗ |
| Nov 12, 2025 | Results ↗ |
| Oct 20, 2025 | Material agreement · Unregistered share sale ↗ |
| Oct 16, 2025 | Material agreement · Results · Unregistered share sale · Regulation FD ↗ |
| Sep 18, 2025 | Material agreement · New obligation ↗ |
| Aug 12, 2025 | Results ↗ |